<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02374684</url>
  </required_header>
  <id_info>
    <org_study_id>HubeiBMITI- CM2010-01-I</org_study_id>
    <nct_id>NCT02374684</nct_id>
  </id_info>
  <brief_title>Tolerability, Safety and Pharmacokinetic Study Of Methosulide in Healthy Adult Subjects</brief_title>
  <official_title>A Within-group Randomized, Double-Blind, Placebo-Controlled, Single/ Multiple Dose Study to Assess the Safety , Tolerability, Pharmacokinetics and Food Effect of Methosulide After Oral Administration In Healthy Adult Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hubei Biological Medicine Industrial Technology Institute Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academy Military Medical Science, China</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hubei Biological Medicine Industrial Technology Institute Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability, and to evaluate the&#xD;
      pharmacokinetic characteristics and food effect of Methosulide after oral administration in&#xD;
      healthy adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Dose-escalation study of single oral administration of Methosulide in healthy adults to&#xD;
           assess the safety and tolerability.&#xD;
&#xD;
        2. Multiple-dose study of Methosulide in healthy adults to assess the safety and&#xD;
           tolerability.&#xD;
&#xD;
        3. Dose-escalation study of single oral administration of Methosulide in healthy adults to&#xD;
           evaluate the pharmacokinetic characteristics&#xD;
&#xD;
        4. Multiple-dose study of Methosulide in healthy adults to evaluate the pharmacokinetics&#xD;
           characteristics&#xD;
&#xD;
        5. Single dose,and cross-over study of Methosulide in healthy adults to evaluate the&#xD;
           pharmacokinetic characteristics and effect of food.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single and repeated oral administration of Methosulide as measured by the frequency of drug-related clinical adverse events in healthy adults.</measure>
    <time_frame>Period I: single dose,Baseline - 7 Days;Period II: repeated dose,Baseline - 14 Days</time_frame>
    <description>Adverse events, vital signs, electrocardiograms, physical exams, and clinical laboratory assessments will be assessed prior to, during, and after treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of single oral administration of Methosulide and effect of food in healthy adults.</measure>
    <time_frame>Baseline - 7 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of single oral administration of Methosulide and effect of food in healthy adults.</measure>
    <time_frame>Baseline - 7 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under curve(AUC) of single oral administration of Methosulide and effect of food in healthy adults.</measure>
    <time_frame>Baseline - 7 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2α of single oral administration of Methosulide and effect of food in healthy adults.</measure>
    <time_frame>Baseline - 7 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2β of single oral administration of Methosulide and effect of food in healthy adults.</measure>
    <time_frame>Baseline - 7 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd of single oral administration of Methosulide and effect of food in healthy adults.</measure>
    <time_frame>Baseline - 7 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cls of single oral administration of Methosulide and effect of food in healthy adults.</measure>
    <time_frame>Baseline - 7 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Css of repeated oral administration of Methosulide in healthy adults.</measure>
    <time_frame>Baseline - 14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of repeated oral administration of Methosulide in healthy adults.</measure>
    <time_frame>Baseline - 14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of repeated oral administration of Methosulide in healthy adults.</measure>
    <time_frame>Baseline - 14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under curve(AUC) of repeated oral administration of Methosulide in healthy adults.</measure>
    <time_frame>Baseline - 14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2α of repeated oral administration of Methosulide in healthy adults.</measure>
    <time_frame>Baseline - 14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2β of repeated oral administration of Methosulide in healthy adults.</measure>
    <time_frame>Baseline - 14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd of repeated oral administration of Methosulide in healthy adults.</measure>
    <time_frame>Baseline - 14 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cls of repeated oral administration of Methosulide in healthy adults.</measure>
    <time_frame>Baseline - 14 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Methosulide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methosulide, oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methosulide</intervention_name>
    <description>Tolerability Study:&#xD;
Period I:Single oral administration,dose-escalation of Methosulide(six dose groups:25mg-250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg ,group 2:depending on the adverse drug reaction,150mg/250mg)&#xD;
Pharmacokinetic Study:&#xD;
Period I:Single oral administration,dose-escalation of Methosulide(three dose groups:50mg,100mg,200mg/250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg&#xD;
,group 2:depending on the adverse drug reaction,150mg/250mg)&#xD;
Food Effect on the Pharmacokinetics:&#xD;
single dose(100mg),two status(Feeding and fasting), washout period(7 days)</description>
    <arm_group_label>Methosulide</arm_group_label>
    <other_name>CM2010-01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to match with experimental groups</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, between 18 and 45 years of age, Body Mass Index (BMI) between 19～25&#xD;
             kg/m2, Weight &gt; or = 50kg&#xD;
&#xD;
          -  In good health as judged by the investigator&#xD;
&#xD;
          -  Without history of medication within 2 weeks before the test&#xD;
&#xD;
          -  Non-allergic constitution, without known drug allergy&#xD;
&#xD;
          -  Without history of major organ diseases&#xD;
&#xD;
          -  Without other factors affecting drug metabolism, such as smoking (within 2 weeks),&#xD;
             drinking (within 2 weeks), or drug abuse history&#xD;
&#xD;
          -  Signed informed consent form and Fully understood the contents, process and possible&#xD;
             adverse reactions of the test&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of kinds of food or drug allergy, or suffering from allergic diseases or&#xD;
             allergic constitution&#xD;
&#xD;
          -  Presence (in screening stage) or history of the acute/chronic organic diseases or&#xD;
             clinical manifestations: blood system, renal disease, endocrine system, respiratory&#xD;
             system, digestive system, cardiovascular system, nervous system, mental disease,&#xD;
             allergic diseases (including drug allergy, but not including non-treatment,&#xD;
             asymptomatic, seasonal allergy during the period of oral administration)&#xD;
&#xD;
          -  History of abuse of Smoking, alcohol, or other drugs&#xD;
&#xD;
          -  Severe hemorrhage factors to affect the venous blood collection&#xD;
&#xD;
          -  Severe blood loss or blood donation within 3 months before the test&#xD;
&#xD;
          -  Participation in other drug trials within 3 months before the test&#xD;
&#xD;
          -  Usage of drugs known to have damage to the main organs within 3 months before the test&#xD;
&#xD;
          -  Without good compliance, or unable to match with the test&#xD;
&#xD;
          -  with a clinically significant abnormality in routine serological detection: including&#xD;
             Hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus&#xD;
             (HIV) infected&#xD;
&#xD;
          -  For childbearing-aged women only, usage of any hormonal contraceptive methods within 3&#xD;
             months before the drug administration; or unable or unwilling to use non-hormonal&#xD;
             contraceptive methods to contraception from the day of dosing until 14 days after&#xD;
             dosing&#xD;
&#xD;
          -  Be otherwise unsuitable for the study, in the opinion of the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ZHENG Heng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan，Hubei</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>February 5, 2015</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2015</study_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-Inflammatory Agents, Non-Steroidal</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

